✔ 100% Authentic Product
👁️ Currently Viewing 608
Linzolid 400 Tablet 1 Strip
Linzolid is indicated for the treatment of:
- Hospital-acquired (nosocomial) pneumonia
- Community-acquired pneumonia
- Complicated skin and soft tissue infections, including diabetic foot infections (without accompanying osteomyelitis)
- Uncomplicated skin and skin structure infections
- Infections caused by Vancomycin-resistant Enterococcus faecium
Linzolid is ineffective against Gram-negative pathogens. Its safety and efficacy beyond 28 days of continuous use have not been established in clinical trials.
100% Genuine Products, Guaranteed
Safe & Secure Payments, Always
Fast, Secure & Efficient Delivery
Proper Packaging
Cash on Delivery - All over Bangladesh
Regular Delivery - 12-24 Hours, Dhaka City*- Regular Delivery - 24-48 Hours, All Over Bangladesh*
ফ্রি ডেলিভারিঃ - ৯৯৯ টাকা+ অর্ডারে, ঢাকা
শহরে- ফ্রি ডেলিভারিঃ - ২৯৯৯ টাকা+ অর্ডারে, ঢাকার
বাহিরে
✅ Description:
Linezolid is a synthetic antimicrobial agent classified as an oxazolidinone. It exhibits potent activity primarily against aerobic Gram-positive bacteria, some Gram-positive anaerobes, and selected Gram-negative species. Its mechanism involves selective inhibition of bacterial protein synthesis by binding to the 23S ribosomal RNA on the 50S ribosomal subunit. This action prevents the assembly of a functional 70S initiation complex, which is essential for bacterial translation.
Bacteriostatic: Against Enterococci and Staphylococci
Bactericidal: Against most strains of Streptococci
Relevant Products / প্রাসঙ্গিক পণ্য
✔️ Dosage & Administration
Linzolid is available as oral tablets and intravenous infusion. It can be taken with or without food. IV infusion must be administered over 30–120 minutes.
| Infection | Pediatric (0–11 yrs) | Adults & Adolescents (12+ yrs) | Duration |
|---|---|---|---|
| Nosocomial pneumonia | 10 mg/kg every 8 hr (oral/IV) | 600 mg every 12 hr (oral/IV) | 10–14 days |
| Community-acquired pneumonia, Complicated SSTI | 10 mg/kg every 8 hr (oral/IV) | 600 mg every 12 hr (oral/IV) | 14–28 days |
| Uncomplicated SSTI | <5 yrs: 10 mg/kg every 8 hr (oral) 5–11 yrs: 10 mg/kg every 12 hr (oral) | Adults: 400 mg every 12 hr (oral) Adolescents: 600 mg every 12 hr (oral) | 10–14 days |
Neonates (<7 days, <34 weeks GA): Begin with 10 mg/kg every 12 hours. If clinical response is inadequate, 10 mg/kg every 8 hours may be considered. By day 7, switch to 10 mg/kg every 8 hours.
No dose adjustment is needed when switching between IV and oral forms.
IV Administration: Inspect the infusion visually for particulates. A yellow tint may develop without affecting potency. Avoid series connections or adding substances to the solution. Discard any unused solution after a single use.
Hepatic impairment: No adjustment needed in mild-to-moderate cases. Not studied in severe hepatic dysfunction.
Pediatric CNS infections: Not recommended for empirical treatment.
✔️ Adverse Effects
- Diarrhea
- Nausea
- Headache
✔️ Drug Interactions
With medications: Linezolid is a reversible non-selective MAO inhibitor. It may enhance the pressor response to sympathomimetics and pose a risk of serotonin syndrome when co-administered with SSRIs, TCAs, triptans, buspirone, or meperidine.
With food: Patients should avoid tyramine-rich foods (e.g., aged cheese, fermented meats).
✔️ Contraindications
- Known hypersensitivity to Linezolid or its components.
- Concomitant use with MAO inhibitors (e.g., phenelzine, isocarboxazid) or within 2 weeks of their use.
- Conditions such as uncontrolled hypertension, pheochromocytoma, thyrotoxicosis, carcinoid syndrome, or concurrent use of certain serotonergic or adrenergic agents.
- Others: Oral/vaginal candidiasis, hypertension, indigestion, abdominal discomfort, itching, and tongue discoloration.
✔️ Use in Pregnancy and Lactation
Pregnancy: Limited data suggest no major fetal risks. Use only if needed.
Breastfeeding: Linezolid is present in breast milk. Monitor infants for gastrointestinal symptoms.
✔️ Precautions & Warnings
- Monitor CBC weekly, especially with prolonged use (>2 weeks), in patients with prior myelosuppression or receiving other marrow-suppressing drugs.
- If visual disturbances occur, prompt ophthalmic evaluation is necessary.
- Not recommended for catheter-related bloodstream or catheter-site infections.
- Be alert for Clostridium difficile-associated diarrhea (CDAD), which may occur up to 2 months post-treatment.
- Monitor blood pressure in susceptible individuals.
- Patients with unexplained acidosis or hypoglycemia should receive immediate medical attention and potential treatment adjustments.
⚠️Disclaimer:
At ePharma, we’re committed to providing accurate and accessible health information. However, all content is intended for informational purposes only and should not replace medical advice from a qualified physician. Please consult your healthcare provider for personalized guidance. We aim to support, not substitute, the doctor-patient relationship.
